Novo Nordisk A/S (NYSE:NVO) Stock Sees Unusually High Call Option Buying

Key Points

• Traders bought 63,116 call options on Novo Nordisk—14% above typical daily volume—and shares rose 6.4% to $42.77.
• Novo beat quarterly earnings and revenue estimates, with obesity-drug sales up 22%, and raised its 2026 sales and operating-profit outlook amid stronger demand, including for Wegovy.
• Analysts remain cautious overall: the stock has a consensus “Hold” rating from 26 analysts, while diabetes weakness and pricing pressure remain risks.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was the target of unusually large options trading on Wednesday. Traders purchased 63,116 call options on the stock. This represents an increase of 14% compared to the typical daily volume of 55,182 call options.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NVO shares. DZ Bank reiterated a "neutral" rating on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Jefferies Financial Group restated a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Citigroup restated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Friday, October 9th. Barclays reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $59.44.

Novo Nordisk A/S Trading Up 6.4%

Shares of NVO stock traded up $2.58 on Wednesday, hitting $42.77. The stock had a trading volume of 13,690,729 shares, compared to its average volume of 16,399,420. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a fifty day moving average price of $40.97 and a two-hundred day moving average price of $44.15. The firm has a market cap of $190.96 billion, a P/E ratio of 10.43, a PEG ratio of 1.37 and a beta of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.73 by $0.15. The business had revenue of $12 billion for the quarter, compared to the consensus estimate of $11.07 billion. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. As a group, analysts forecast that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat Q3 earnings and revenue estimates, reporting $0.88 per share versus $0.73 expected and $12 billion in revenue versus $11.07 billion expected. Obesity-drug sales rose 22%, supporting the results. Article: NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 sales and operating-profit outlook. Stronger obesity-treatment demand, including outside the U.S., and Wegovy pill sales that reportedly exceeded expectations helped drive the upgrade. Article: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
• Positive Sentiment: CEO Mike Doustdar said patient volumes have grown strongly despite pricing-related pressure, and played down the prospect of dramatic changes to the company’s business environment. These comments may ease investor concerns about pricing and policy risks. Article: Novo CEO Brushes Off Post-Midterm Drug-Pricing Fears
• Neutral Sentiment: Novo disclosed that CFO Karsten Munk Knudsen will leave the company. The announcement adds a leadership transition to the news flow, but no further details on its impact were provided. Article: Novo Nordisk's CFO Karsten Munk Knudsen to leave company
• Negative Sentiment: Diabetes weakness and pricing pressures remain risks to growth. Impairment charges also weighed on reported operating profit, although adjusted results were stronger than expected. Article: Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%

Institutional Trading of Novo Nordisk A/S

Large investors have recently bought and sold shares of the business. CoreCap Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 4.7% in the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company's stock valued at $256,000 after purchasing an additional 242 shares in the last quarter. Claro Advisors Inc. raised its holdings in shares of Novo Nordisk A/S by 1.2% during the 3rd quarter. Claro Advisors Inc. now owns 21,868 shares of the company's stock worth $829,000 after buying an additional 256 shares in the last quarter. Carson Advisory Inc. raised its holdings in shares of Novo Nordisk A/S by 2.2% during the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company's stock worth $453,000 after buying an additional 268 shares in the last quarter. Byrne Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 9.7% during the 3rd quarter. Byrne Asset Management LLC now owns 3,055 shares of the company's stock worth $114,000 after buying an additional 270 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT grew its position in Novo Nordisk A/S by 0.6% in the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company's stock valued at $1,726,000 after acquiring an additional 272 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.